Hepatocellular Carcinoma
Slides: Real-world dosing of regorafenib in patients with  unresectable hepatocellular carcinoma (uHCC):  Final analysis of the prospective, observational  REFINE study

Released: January 26, 2023

Expiration: January 25, 2024

Richard S. Finn
Richard S. Finn, MD

Activity

Progress
1
Course Completed